Bone News and Research

RSS

$Hip fracture patients more likely to be evaluated for osteoporosis than wrist fracture patients$

Hip fracture patients more likely to be evaluated for osteoporosis than wrist fracture patients

A study published in the October 2009 issue of the Journal of Bone and Joint Surgery suggests a disconnect between the way wrist-fracture patients and those with a spine or hip fracture are managed and evaluated. The study, conducted in 2007 among 97 percent of the women in Korea, reviewed the incidence of fractures around the hip, spine, and wrist in female patients age 50 and older and the prescription frequencies of bone density scans for osteoporosis, along with the use of medications for its treatment.

3 Oct 2009

Study points to subtle differences between boys and girls' attitudes to multiple drugs

New research by Weill Cornell Medical College researchers looks at the specific ways parents and peers influence teenagers to smoke, drink and use marijuana in combination.

3 Oct 2009

New technique to repair damaged bones developed

Spire Healthcare's private hospital in Southampton has pioneered a new technique which uses stem cells to repair damaged bones. Orthopaedic Surgeon, Mr Douglas Dunlop carried out the procedure which may prevent thousands of people from needing hip replacement operations in the future.

3 Oct 2009

New study reports PRP treatment and its use in sports medicine

Platelet -rich plasma (PRP) is currently used as an alternative treatment method for several common orthopaedic-related sports medicine conditions.

3 Oct 2009

Cardium announces positive results from the Phase 1 / 2 clinical study of Excellarate

Cardium Therapeutics announced plans to report on preliminary safety and efficacy data from its Matrix Phase 2b Excellarate clinical study. Based on guidance from Cardium's independent clinical data management company which is currently completing the statistical analysis of all data for the Matrix clinical trial, Cardium expects to receive the locked unblinded data set and be in position to announce preliminary results on or before October 14, 2009.

3 Oct 2009

NK cells keep T cells in check: Study

Natural killer, or NK cells, are part of our innate immune system. A healthy body produces them to respond early during infection. They are activated and they kill cells infected with a given virus.

3 Oct 2009

DelSite's assests acquired by Nanotherapeutics

Nanotherapeutics, Inc., a privately held specialty biopharmaceutical company, announced today that it had acquired certain assets from DelSite (formerly Carrington Laboratories, Inc.) out of Chapter 7 bankruptcy proceedings in the U.S. Bankruptcy Court for the Northern District of Texas, Dallas Division.

3 Oct 2009

Five-year follow-up study reveals the efficacy of OsseoSpeed implant

The five-year follow-up study was made by Dr. Steveling and co-workers at the Department of Oral and Maxillofacial Surgery at the Heidelberg University in Germany. The conclusion is that the OsseoSpeed implant shows very good results also in compromised sites when using an early loading protocol.

3 Oct 2009

ETEX' Equivabone receives additional FDA clearance for use in posterolateral spine fusion

ETEX Corporation, an advanced biomaterials company, announced today additional FDA 510(k) cleared indications for EquivaBone®. EquivaBone was the first FDA cleared hard-setting osteoinductive material and is the only osteoinductive bone graft substitute that provides a continuous nanocrystalline calcium phosphate scaffold.

3 Oct 2009

Co-marketing partnership between Enzo Life Sciences and BioTek Instruments

Enzo Biochem, Inc. announced today a co-marketing partnership between its Enzo Life Sciences subsidiary, a world leader in non-radioactive probe technology, and BioTek Instruments, a privately held global leader in the development, manufacture and sale of microplate instrumentation for drug discovery and life science applications, involving powerful, integrated solutions for high throughput live cell analysis.

3 Oct 2009

International Society for Hip Arthroscopy to focus on new procedures for hip surgery at its inaugural meeting

Recent advances in diagnostic imaging techniques and hip arthroscopy procedures are giving physicians and surgeons better tools with which to treat hip pain. The 2009 International Society for Hip Arthroscopy meeting, hosted by Hospital for Special Surgery in New York, brings together leading surgeons from all over the world to take an in-depth look at hip arthroscopy and its potential benefits.

3 Oct 2009

CVRx commences enrollment in study evaluating the Rheos System to treat heart failure

CVRx, Inc. reported the first enrollment of a patient in the HOPE4HF Trial, a study that is evaluating the Rheos System to treat heart failure. The Rheos System uses Baroreflex Activation Therapy® technology, an entirely new non-pharmaceutical approach designed to treat cardiovascular disease. The HOPE4HF Trial is being conducted under an approved investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA).

1 Oct 2009

Resorbable Orthopedics becomes wholly owned subsidiary of Wound Management Technologies

Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM) a rapidly growing provider of specialty medical products, announced today it has closed on its acquisition of Resorbable Orthopedics LLC, a private company with patented technologies including a resorbable bone wax and a delivery system for orthopedic bone void fillers, among others.

1 Oct 2009

Stem cell therapy aims to prevent permanent damage from heart attacks

All patients arriving at UCSF's Emergency Department with heart attack will continue to be treated with standard measures. Patients who meet the medical criteria for the trial will be able to elect to receive the stem cell therapy within seven days after their heart attack.

1 Oct 2009

Retailers join to support breast cancer research

This October, retailers nationwide are joining the fight against breast cancer by offering pink ribbon products that benefit research, treatment and education programs at City of Hope, one of the nation’s leading cancer research and treatment centers. From skin and hair care treatments to apparel to office products, consumers can feel good about their purchases and help support lifesaving cancer research.

1 Oct 2009

Six Indiana and Alabama hospitals settle whistleblower lawsuit

Three hospitals in Indiana and three hospitals in Alabama have agreed to pay the federal government a total of $8.3 million to settle a whistleblower lawsuit that alleged the hospitals deliberately overcharged Medicare for routine, minimally-invasive back surgery.

1 Oct 2009

Gamida Cell publishes article evaluating Stemex for leukemia and lymphoma

Gamida Cell announced today the publication of an article evaluating carlecortemcel-l, the generic name of what is widely known as "StemEx", as a therapy for blood cancers such as leukemia and lymphoma. The article, carlecortemcel-l, an ex vivo expanded umbilical cord blood cell graft for allogeneic transplantation, written by Dr. Ka Wah Chan and Dr. Demetrios Petropoulos, will be published in the November 2009 issue of Expert Opinion on Biological Therapy.

1 Oct 2009

OSI Systems to deliver DexaCare bone densitometers for international customer

OSI Systems, Inc., a vertically-integrated provider of specialized electronic products for critical applications in the Security and Healthcare industries, today announced that it has received a contract for approximately $1.3 million from an undisclosed international customer to deliver its DTX-200 DexaCare® bone densitometers.

1 Oct 2009

St. Mary Medical Center offers Frameless Stereotactic Radiosurgery treatment to fight cancer

For patients diagnosed with a brain tumor, St. Mary Medical Center is among the first in the region to offer Frameless Stereotactic Radiosurgery (SRS) as a breakthrough treatment to fight cancer. Frameless Stereotactic Radiosurgery is a one-time application of a large-dose radiation precisely targeting a tumor.

1 Oct 2009

New medical breakthrough by Bioheart for treatment of patients with heart disorders

Bioheart, Inc. offers yet another medical breakthrough with the next-level stem cell treatment for cardiac patients. The stem cells aid in limiting damage due to a cardiac event and promote angiogenesis or formation of new blood vessels.

1 Oct 2009

Bone News and Research

Hip fracture patients more likely to be evaluated for osteoporosis than wrist fracture patients

Study points to subtle differences between boys and girls' attitudes to multiple drugs

New technique to repair damaged bones developed

New study reports PRP treatment and its use in sports medicine

Cardium announces positive results from the Phase 1 / 2 clinical study of Excellarate

NK cells keep T cells in check: Study

DelSite's assests acquired by Nanotherapeutics

Five-year follow-up study reveals the efficacy of OsseoSpeed implant

ETEX' Equivabone receives additional FDA clearance for use in posterolateral spine fusion

Co-marketing partnership between Enzo Life Sciences and BioTek Instruments

International Society for Hip Arthroscopy to focus on new procedures for hip surgery at its inaugural meeting

CVRx commences enrollment in study evaluating the Rheos System to treat heart failure

Resorbable Orthopedics becomes wholly owned subsidiary of Wound Management Technologies

Stem cell therapy aims to prevent permanent damage from heart attacks

Retailers join to support breast cancer research

Six Indiana and Alabama hospitals settle whistleblower lawsuit

Gamida Cell publishes article evaluating Stemex for leukemia and lymphoma

OSI Systems to deliver DexaCare bone densitometers for international customer

St. Mary Medical Center offers Frameless Stereotactic Radiosurgery treatment to fight cancer

New medical breakthrough by Bioheart for treatment of patients with heart disorders

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News